More on ASND
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $263.04 |
|
|||
| Open | $261.65 | ||||
| 52 Wk High | $21.79 | ||||
| 52 Wk Low | $11.92 | ||||
| Day High | $266.63 | ||||
| Day Low | $256.28 | ||||
| P/E | N/A | ||||
| EPS | $-0.07 | ||||
| Volume | 610,706 | ||||
- Ascendis Pharma (ASND) PT Raised to $312 at Oppenheimer
- Ascendis Pharma (ASND) PT Lowered to $273 at Morgan Stanley
- Ascendis Pharma (ASND) PT Lowered to $304 at BofA Securities
- Ascendis Pharma (ASND) PT Lowered to $330 at Jefferies
- Ascendis Pharma (ASND) PT Lowered to $326 at Stifel
- H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)
- H.C. Wainwright Starts Ascendis Pharma (ASND) at Buy
- Ascendis to present 2-year navepegritide trial data at ISDS 2026
- Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
- Form 4 Ascendis Pharma A/S For: Aug 14 Filed by: BIENAIME JEAN JACQUES
Entities mentioned with ASND
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
